US 2022/0175731 A1Published application

Jak1 pathway inhibitors for the treatment of vitiligo

AssigneeIncyte Corporation

InventorsPaul Smith, Kurt Andrew Brown, Michael D. Howell, Fiona Kuo, James Lee, Leandro Luiz Dos Santos, Beth Rumberger

Life of this patent

Estimating the term…

Abstract

This disclosure relates to JAK1 pathway inhibitors and their use in treating vitiligo.

Claims11

Dependent claims

A method for treating vitiligo in a subject, said method comprising administering to the subject a therapeutically effective amount of a JAK1 pathway inhibitor, or a pharmaceutically acceptable salt thereof.

Dependencies are inferred from the claim text.

Facts

Application: 17/545,377Filed 8 Dec 2021
Priority: 8 Dec 2020
Published: 9 Jun 2022
Term ends: Not estimatedThe source records don’t support an estimate.

Classification8 codes

A61K 31/415
Having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole: 1,2-Diazoles
A61K 31/4155
1,2-Diazoles: non condensed and containing further heterocyclic rings
A61K 31/437
Ortho- or peri-condensed with heterocyclic ring systems: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring…
A61K 31/519
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim: ortho- or peri-condensed with heterocyclic rings

Family

Application63/122,574Us provisional application · filed 8 Dec 2020
Application63/246,688Us provisional application · filed 21 Sep 2021
US 11,957,661 B2Related patent
US 2022/0175731 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results